Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). (Q46723284)
Jump to navigation
Jump to search
scientific article published in March 2008
Language | Label | Description | Also known as |
---|---|---|---|
English | Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). |
scientific article published in March 2008 |
Statements
1 reference
Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). (English)
1 reference
1 reference
1 March 2008
1 reference
70
1 reference
4
1 reference
974-977
1 reference